Introduction
============

Gastric cancer remains a major public health concern as it represents the fourth most common cancer and the second leading cause of cancer-related deaths worldwide.[@b1-ott-7-1625]--[@b3-ott-7-1625] Nevertheless, the incidence and mortality associated with gastric cancer have decreased considerably over the past 50 years in most areas of the world.[@b1-ott-7-1625] Although conventional diagnostic methods such as gastric endoscopy have contributed to this reduction by enabling early diagnosis, many patients are diagnosed with advanced gastric cancer and have a poor prognosis. Thus, more sensitive tumor markers are urgently needed to improve screening, diagnosis, prognostic evaluation, and tumor grading of gastric cancer. Several potential approaches have been proposed to find suitable marker candidates, and the recent discovery of long-non-coding RNAs (lncRNAs) provides a new opportunity to resolve this challenge. LncRNAs are non-protein-coding transcripts longer than 200 nucleotides[@b4-ott-7-1625] and are widely distributed in the genome; indeed, more than 90% of the human genome is composed of non-coding RNAs.[@b5-ott-7-1625] There is mounting evidence that many lncRNAs are dysregulated in various cancers and play important roles in tumorigenesis and invasion.[@b6-ott-7-1625]--[@b8-ott-7-1625] Thus, lncRNAs may serve as useful tumor markers and therapeutic targets for controlling malignant tumors. In the current study, we investigated the expression of plasmacytoma variant translocation 1 (*PVT1*), a documented oncogenic lncRNA,[@b9-ott-7-1625] in gastric cancer and examined its association with clinical features in patients with gastric cancer to reveal its potential as a biomarker and therapeutic target.

Materials and methods
=====================

Thirty-three tumor tissues and corresponding non-cancerous tissues were obtained at the time of surgery from June 2012 to October 2013 at the First Affiliated Hospital and Union Hospital of Fujian Medical University, Fuzhou, Fujian, People's Republic of China. Following excision, the gastric cancer and non-cancerous tissues were immediately frozen in liquid nitrogen and stored at −80°C until use.

The SGC7901 gastric cancer cell line was obtained from the China Center for Type Culture Collection (Wuhan, People's Republic of China). Paclitaxel-resistant SGC7901 cells were developed in our laboratory and cultured in 450 μg/L paclitaxel. Total mRNA was isolated using TRIzol^®^ Reagent (Life Technologies Corporation, Carlsbad, CA, USA), according to the manufacturer's protocol.

The paclitaxel-resistant cell line was developed by culture of an SGC7901 gastric cancer cell line in vitro with an increasing gradient of concentrations of paclitaxel intermittently over 6 months. The initial concentration of paclitaxel was 25 μg/L. Forty-eight hours later, medium containing 25 μg/L paclitaxel was replaced with routine medium until the SGC7901 cells were growing in exponential period, after which the paclitaxel concentration was increased to 50 μg/L. Six months later, the final concentration of paclitaxel was 450 μg/L, and the resistance in paclitaxel-resistant SGC7901 cells was detected with MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and compared with normal SGC7901 cells. The MTT assay was performed after 48 hours of incubation with paclitaxel (five concentrations in a multiple proportion dilution from 160 to 10 μg/L), the plates were centrifuged to pellet the cells, the supernatant was removed, and 20 μL of 5 mg/mL MTT was added in 180 μL of medium, followed by incubation for 4 hours at 37°C in a humid, 5% CO~2~ atmosphere. Next, the plates were centrifuged again, the supernatant was removed, and the insoluble formazan crystals were dissolved in dimethyl sulfoxide. Absorbance was read at 490 nm. The half maximal inhibitory concentration (IC~50~) was calculated using the Spearman--Kärber cytopathic effect method.[@b10-ott-7-1625] Before lncRNA microarray analysis, the MTT assay showed IC~50~ values for SGC7901 and paclitaxel-resistant SGC7901 of 22.16±0.31 μg/L and 141.31±0.9 5 μg/L, respectively. The difference was statistically significant (*P*\<0.001). The drug resistance index for paclitaxel-resistant SGC7901 cells was 6.38.

Microarray analysis
-------------------

Tissue samples (two gastric cancer tissues and two corresponding non-cancerous tissues) and SGC7901 cells were used to synthesize double-stranded complementary DNA, which was labeled according to the protocol of the Amplification and Labeling Kit for Microarray (CapitalBio Corporation, Beijing, People's Republic of China). The labeled complementary DNA was hybridized to the Agilent Human LncRNA 4×180 K Expression Microarray (Agilent Technologies Inc., Santa Clara, CA, USA), which contains 37,000 human lncRNAs and 34,000 mRNA probes (CapitalBio Corporation). After hybridization and washing, the processed slides were scanned with a G2565CA microarray scanner (Agilent Technologies). Raw data were extracted as paired files using Feature Extraction software (Agilent Technologies). The raw data were normalized using GeneSpringGX11 software (Agilent Technologies) with default parameters. Differential expression of lncRNAs was screened in genes flagged as "detected" by the software. Differentially expressed genes were identified through the random variance model.

Quantitative polymerase chain reaction
--------------------------------------

Total mRNA from 31 gastric cancer tissues and 31 corresponding non-tumor tissues was isolated using TRIzol Reagent according to the manufacturer's protocol. Complementary DNAs from all samples were synthesized from 1.0 μg of total RNA using the PrimeScript^®^ 1st strand cDNA synthesis kit (TaKaRa Bio, Shiga, Japan) following the manufacturer's protocol. *PVT1* expression levels were quantified using a LightCycler Brilliant SYBR Green quantitative reverse transcriptase polymerase chain reaction (PCR) kit (Roche Applied Science, Indianapolis, IN, USA) following the manufacturer's protocol, with the following primers: forward, TTGGCACATACAGCCATCAT and reverse, GCAGTAAAAGGGGAACACCA. The length of the quantitative PCR product was 102 base pairs. The *PVT1* expression level in each sample was normalized to the respective human β-actin expression level, with the following primers: forward, AGCGAGCATCCCCCAAAGTT; and reverse, GGGCACGAAGGCTCATCATT (product length, 285 base pairs). The specificity of each PCR reaction was confirmed by melting curve analysis.

Statistical analysis
--------------------

The statistical significance of differences between cancerous and adjacent non-cancerous tissues was determined using the Wilcoxon signed-rank test. The correlation between *PVT1* expression and patient clinicopathological variables was analyzed by the Fisher's exact probability test. A *P*-value \<0.05 was regarded as being statistically significant. All statistical analyses were performed using Statistical Package for the Social Sciences version 11.0 software for Windows (SPSS Inc., Chicago, IL, USA).

Results
=======

Microarray analysis
-------------------

A total of 252 lncRNAs were upregulated in gastric cancer tissues identified from the microarrays. Twenty-eight of the upregulated lncRNAs had an obvious fold change in the gastric cancer tissues when compared with corresponding non-tumor tissues ([Figure 1](#f1-ott-7-1625){ref-type="fig"} and [Table 1](#t1-ott-7-1625){ref-type="table"}). In total, 545 lncRNAs were upregulated in paclitaxel-resistant SGC7901 cells when compared with normal SGC7901 cells (data supplied). *PVT1* expression levels in the gastric cancer tissues were 5.128 and 5.755 times higher than those in the corresponding non-tumor tissues ([Table 1](#t1-ott-7-1625){ref-type="table"}). In addition, *PVT1* expression was 3.715 times higher in paclitaxel-resistant SGC7901 cells than in normal SGC7901 cells (data supplied). Based on these results and recent discoveries concerning the role of *PVT1* in tumorigenesis and resistance to chemotherapy,[@b9-ott-7-1625],[@b11-ott-7-1625] we studied the expression of *PVT1* further in patients with gastric cancer and its correlation with clinical features.

*PVT1* expression
-----------------

*PVT1* expression levels in cancerous and adjacent noncancerous tissues from patients with gastric cancer were examined by quantitative reverse transcriptase PCR and normalized by β-actin expression levels. The Wilcoxon signed-rank test showed that *PVT1* expression was significantly higher in cancerous tissues than in adjacent noncancerous tissues (*P*=0.0414).

*PVT1* expression and clinical features
---------------------------------------

In [Figure 2](#f2-ott-7-1625){ref-type="fig"} and [Table 2](#t2-ott-7-1625){ref-type="table"}, the human gastric cancer tissues are classified according to *PVT1* expression level into a high *PVT1* expression group (*PVT1* in cancer tissue/*PVT1* in non-cancerous tissue \>1.0) and a low *PVT1* expression group (*PVT1* in cancer tissue/*PVT1* in non-cancerous tissue \<1.0). The association of *PVT1* expression with the clinicopathological features of patients with intestinal-type gastric cancer is summarized in [Table 2](#t2-ott-7-1625){ref-type="table"}. A significant association was found between *PVT1* expression and lymph node metastasis (*P*=0.022). No correlation was found between *PVT1* expression and patient age, sex, tumor metastasis, or stage of gastric cancer.

Discussion
==========

A set of lncRNAs showed differential expression between human gastric cancer and non-cancerous tissue. Thus, these lncRNAs may play important roles in the carcinogenesis and invasiveness of human gastric cancer and are potential candidates for new biomarkers and therapeutic targets.[@b6-ott-7-1625]--[@b9-ott-7-1625]

*PVT1*, one such oncogenic lncRNA, is a large (\>300 kb) locus located 57 kb downstream of *MYC* on human chromosome 8q24.[@b12-ott-7-1625]--[@b15-ott-7-1625] Although no protein product or regulatory RNA has yet been identified among *PVT1* transcripts, the importance of this locus has caught the attention of many researchers, as it is a site of both tumorigenic translocations and retroviral insertions. Translocation breakpoints within either the *MYC* or *PVT1* locus are responsible for the characteristic lesions associated with Burkitt lymphoma and mouse plasmacytomas.[@b13-ott-7-1625]--[@b18-ott-7-1625]

Coamplification of human *MYC* and *PVT1* has been shown to correlate with rapid progression of breast cancer as well as poor clinical survival in postmenopausal women and in patients with HER2-positive breast cancer.[@b19-ott-7-1625] Recent studies have discovered a cluster of miRNAs within the *PVT1* genomic DNA region, including miR1204, miR1205, miR1206, miR1207, and miR1208.[@b20-ott-7-1625],[@b21-ott-7-1625] The regulatory functions of these miRNAs within MYC-PVT1 locus are complicated, only the function of miR1204 has been partially proved. MiR1204 plays an antiproliferative role, inducing cell death or cell cycle arrest, as a functional target of p53 at the *PVT1* locus. MiR1204 expression can also increase p53 levels, suggesting there is a positive feedback between miR-1204 and p53.[@b22-ott-7-1625] So far, at least one *PVT1* transcript microRNA product, miR1204, has been shown to be overexpressed and is thus defined as oncogenic.[@b9-ott-7-1625],[@b22-ott-7-1625] These additional non-coding RNA transcripts, exonic *PVT1* sequences, and other miRs are now thought to be either transcriptional byproducts of miR1204 regulation or additional functional targets, but no further evidence is provided. So, except for two aspects of the mechanism of *PVT1* in the prognosis of cancer (including a positive feedback regulation with p53 and coamplification with *MYC*), more studies need to be directed to the complex networks between *PVT1*, p53, *MYC*, and other genes.

In this study, we examined the expression of lncRNAs with 77×10^3^ probes from the Agilent Human 4×180 K Microarray to identify specific lncRNA markers for human gastric cancers at the gene level. These probes correspond to 37,000 lncRNAs and 34,000 mRNAs. We also compared lncRNA expression between an SGC7901 human gastric cancer cell line and a paclitaxel-resistant SGC7901 cell line. The differential expression observed may reveal the mechanism of and biomarkers for paclitaxel resistance in human gastric cancer. Based on the microarray results and in light of recent reports,[@b11-ott-7-1625],[@b13-ott-7-1625]--[@b19-ott-7-1625] we ranked *PVT1* as the lncRNA with the highest potential as a biomarker and a therapeutic target for gastric cancer.

In order to compensate for the deficiency of clinical cases in the microarray analysis and to develop a convenient and economical method for large-scale clinical studies, we used the quantitative PCR technique to confirm the relevance of *PVT1* as a biomarker for gastric cancer. Our results clearly show that *PVT1* expression is significantly enhanced in gastric cancer tissues when compared with non-cancerous tissues of the stomach. A high level of *PVT1* expression was also associated with lymph node metastasis in patients with gastric cancer. No correlation was found between *PVT1* expression and age, sex, tumor, metastasis, or stage of gastric cancer.

In conclusion, we demonstrated that *PVT1* is highly expressed in human gastric cancer. Enhanced expression of *PVT1* was associated with invasion to the lymph nodes and with resistance to paclitaxel. Therefore, these results indicate that *PVT1* is a potential candidate as a biomarker for gastric cancer. Screening for *PVT1* expression could potentially improve early diagnosis, therapy, and drug resistance, and thus improve quality of life for patients with gastric cancer.
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###### 

Twenty-eight candidate lncRNAs expressed with fold changes in two gastric cancer tissues, compared with corresponding non-tumor tissues (only the most obvious data are shown for the lncRNAs with different transcripts)

  Fold change of T1 vs N1   Fold change of T2 vs N2   Gene biotype             Ensemble gene ID   HGNC symbol
  ------------------------- ------------------------- ------------------------ ------------------ ----------------
  27.20002                  104.10264                 Antisense                ENSG00000238133    MLK7-AS1
  16.414074                 4.819842                  LncRNA                   ENSG00000258294    RP11-314D7.1
  12.021113                 5.851729                  LncRNA                   ENSG00000236039    AC019117.2
  10.219363                 5.664894                  LncRNA                   ENSG00000241163    RP11-398A8.3
  8.035696                  3.0575392                 LncRNA                   ENSG00000222041    LINC00152
  6.8010974                 2.6033688                 LncRNA                   ENSG00000226598    AC017060.1
  5.912395                  4.000447                  Antisense                ENSG00000224078    SNHG14
  5.128479                  5.754559                  LncRNA                   ENSG00000249859    *PVT1*
  4.606247                  4.3609843                 LncRNA                   ENSG00000167117    LINC00483
  3.909583                  2.458897                  LncRNA                   ENSG00000244306    CTD-2314B22.3
  3.8943083                 4.077277                  LncRNA                   ENSG00000224397    RP11-290F20.3
  3.698091                  5.106683                  Antisense                ENSG00000243766    HOTTIP
  3.5476947                 4.3146453                 Antisense                ENSG00000254560    RP11-1L12.3
  3.3448012                 4.3363175                 Antisense                ENSG00000251179    RP11-893F2.9
  3.2606792                 2.2400966                 Polymorphic_pseudogene   ENSG00000244682    FCGR2C
  3.0598006                 3.2264988                 LncRNA                   ENSG00000230061    AP001065.2
  3.0492082                 3.112142                  LncRNA                   ENSG00000233930    RP13-25N22.1
  2.9770749                 4.8328776                 LncRNA                   ENSG00000227888    FAM66A
  2.8799016                 2.383093                  Processed transcript     ENSG00000233283    RP11-357H14.20
  2.8781404                 2.6564493                 Processed transcript     ENSG00000250610    RP11-738E22.2
  2.7795174                 2.031886                  LncRNA                   ENSG00000230944    AC026202.5
  2.7087636                 25.26169                  LncRNA                   ENSG00000204241    RP11-713P17.3
  2.5824153                 2.942296                  LncRNA                   ENSG00000136315    RP11-84C10.2
  2.453376                  2.046279                  LncRNA                   ENSG00000214548    MEG3
  2.4336877                 3.0326896                 LncRNA                   ENSG00000248227    RP11-83C7.1
  2.2753818                 2.2845905                 LncRNA                   ENSG00000256969    RP11-320N7.2
  2.1950364                 4.0923414                 LncRNA                   ENSG00000245975    RP11-30K9.6
  2.125026                  2.8170245                 LncRNA                   ENSG00000235572    RP11-555H7.2

**Abbreviations:** HGNC, Human Genome Nomenclature Committee; lncRNAs, long-noncoding RNAs.

###### 

Association between *PVT1* expression and clinicopathological factors in human gastric cancers

                High *PVT1* expression   Low *PVT1* expression   *P*-value[a](#tfn2-ott-7-1625){ref-type="table-fn"}
  ------------- ------------------------ ----------------------- -----------------------------------------------------
  Age           60.7895±7.0441           64.7500±9.0566          0.1827
  Sex                                                            0.1285
   Male         11                       10                      
   Female       8                        2                       
  T                                                              1.0000
   T1, T2       4                        3                       
   T3, T4       15                       9                       
  N                                                              0.0220
   N0           4                        8                       
   N1, N2, N3   15                       4                       
  M                                                              0.2645
   M0           16                       12                      
   M1           3                        0                       
  Stage                                                          0.0596
   1, 2         5                        8                       
   3, 4         14                       4                       

**Note:**

Fisher's exact probability test.
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